Pharnext SA
PAR:ALPHA
Pharnext SA
Research & Development
Pharnext SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Research & Development
-€12m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Research & Development
-€119.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€40.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Research & Development
-€86.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Research & Development
-$95.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-16%
|
|
|
Abivax SA
PAR:ABVX
|
Research & Development
-€199.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Research & Development?
Research & Development
-12m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Research & Development amounts to -12m EUR.
What is Pharnext SA's Research & Development growth rate?
Research & Development CAGR 5Y
-24%
Over the last year, the Research & Development growth was -122%. The average annual Research & Development growth rates for Pharnext SA have been -42% over the past three years , -24% over the past five years .
